|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HDAC8 |
Gene summary for HDAC8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HDAC8 | Gene ID | 55869 |
| Gene name | histone deacetylase 8 | |
| Gene Alias | CDA07 | |
| Cytomap | Xq13.1 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9BY41 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55869 | HDAC8 | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.23e-13 | -4.85e-01 | 0.0155 |
| 55869 | HDAC8 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.21e-07 | -5.89e-01 | -0.1808 |
| 55869 | HDAC8 | HTA11_3361_2000001011 | Human | Colorectum | AD | 4.79e-03 | -5.11e-01 | -0.1207 |
| 55869 | HDAC8 | HTA11_696_2000001011 | Human | Colorectum | AD | 7.87e-11 | -3.90e-01 | -0.1464 |
| 55869 | HDAC8 | HTA11_866_2000001011 | Human | Colorectum | AD | 7.37e-03 | -2.37e-01 | -0.1001 |
| 55869 | HDAC8 | HTA11_5212_2000001011 | Human | Colorectum | AD | 3.62e-02 | -5.87e-01 | -0.2061 |
| 55869 | HDAC8 | HTA11_866_3004761011 | Human | Colorectum | AD | 5.34e-08 | -4.52e-01 | 0.096 |
| 55869 | HDAC8 | HTA11_8622_2000001021 | Human | Colorectum | SER | 1.54e-03 | -6.62e-01 | 0.0528 |
| 55869 | HDAC8 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.09e-02 | -2.93e-01 | 0.0674 |
| 55869 | HDAC8 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.95e-11 | -4.49e-01 | 0.294 |
| 55869 | HDAC8 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 5.58e-06 | 6.94e-01 | 0.281 |
| 55869 | HDAC8 | A015-C-203 | Human | Colorectum | FAP | 3.60e-30 | -4.46e-01 | -0.1294 |
| 55869 | HDAC8 | A015-C-204 | Human | Colorectum | FAP | 1.89e-05 | -3.69e-01 | -0.0228 |
| 55869 | HDAC8 | A014-C-040 | Human | Colorectum | FAP | 5.42e-06 | -5.20e-01 | -0.1184 |
| 55869 | HDAC8 | A002-C-201 | Human | Colorectum | FAP | 1.70e-11 | -2.76e-01 | 0.0324 |
| 55869 | HDAC8 | A001-C-119 | Human | Colorectum | FAP | 1.28e-11 | -5.75e-01 | -0.1557 |
| 55869 | HDAC8 | A001-C-108 | Human | Colorectum | FAP | 4.71e-14 | -2.79e-01 | -0.0272 |
| 55869 | HDAC8 | A002-C-205 | Human | Colorectum | FAP | 1.87e-23 | -4.98e-01 | -0.1236 |
| 55869 | HDAC8 | A001-C-104 | Human | Colorectum | FAP | 6.45e-05 | -2.50e-01 | 0.0184 |
| 55869 | HDAC8 | A015-C-005 | Human | Colorectum | FAP | 1.22e-02 | -2.30e-01 | -0.0336 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0031647 | Colorectum | AD | regulation of protein stability | 108/3918 | 298/18723 | 6.33e-10 | 5.08e-08 | 108 |
| GO:1903320 | Colorectum | AD | regulation of protein modification by small protein conjugation or removal | 86/3918 | 242/18723 | 9.43e-08 | 4.65e-06 | 86 |
| GO:0051052 | Colorectum | AD | regulation of DNA metabolic process | 116/3918 | 359/18723 | 2.47e-07 | 1.00e-05 | 116 |
| GO:0031396 | Colorectum | AD | regulation of protein ubiquitination | 72/3918 | 210/18723 | 4.50e-06 | 1.21e-04 | 72 |
| GO:0031397 | Colorectum | AD | negative regulation of protein ubiquitination | 34/3918 | 83/18723 | 2.66e-05 | 5.04e-04 | 34 |
| GO:1903321 | Colorectum | AD | negative regulation of protein modification by small protein conjugation or removal | 37/3918 | 95/18723 | 4.49e-05 | 7.83e-04 | 37 |
| GO:0006325 | Colorectum | AD | chromatin organization | 119/3918 | 409/18723 | 4.85e-05 | 8.33e-04 | 119 |
| GO:0032204 | Colorectum | AD | regulation of telomere maintenance | 31/3918 | 80/18723 | 2.01e-04 | 2.67e-03 | 31 |
| GO:0033044 | Colorectum | AD | regulation of chromosome organization | 60/3918 | 187/18723 | 2.25e-04 | 2.94e-03 | 60 |
| GO:0007063 | Colorectum | AD | regulation of sister chromatid cohesion | 12/3918 | 21/18723 | 3.02e-04 | 3.62e-03 | 12 |
| GO:0000723 | Colorectum | AD | telomere maintenance | 43/3918 | 131/18723 | 9.77e-04 | 9.20e-03 | 43 |
| GO:0007062 | Colorectum | AD | sister chromatid cohesion | 23/3918 | 62/18723 | 2.51e-03 | 1.92e-02 | 23 |
| GO:00316471 | Colorectum | SER | regulation of protein stability | 86/2897 | 298/18723 | 2.56e-09 | 2.42e-07 | 86 |
| GO:19033201 | Colorectum | SER | regulation of protein modification by small protein conjugation or removal | 70/2897 | 242/18723 | 6.84e-08 | 4.42e-06 | 70 |
| GO:00313961 | Colorectum | SER | regulation of protein ubiquitination | 62/2897 | 210/18723 | 1.69e-07 | 9.71e-06 | 62 |
| GO:00313971 | Colorectum | SER | negative regulation of protein ubiquitination | 29/2897 | 83/18723 | 9.72e-06 | 3.22e-04 | 29 |
| GO:19033211 | Colorectum | SER | negative regulation of protein modification by small protein conjugation or removal | 30/2897 | 95/18723 | 6.29e-05 | 1.46e-03 | 30 |
| GO:00510521 | Colorectum | SER | regulation of DNA metabolic process | 83/2897 | 359/18723 | 8.03e-05 | 1.77e-03 | 83 |
| GO:00063251 | Colorectum | SER | chromatin organization | 89/2897 | 409/18723 | 4.15e-04 | 6.17e-03 | 89 |
| GO:00322041 | Colorectum | SER | regulation of telomere maintenance | 24/2897 | 80/18723 | 7.57e-04 | 9.73e-03 | 24 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04110 | Colorectum | FAP | Cell cycle | 37/1404 | 157/8465 | 1.44e-02 | 4.77e-02 | 2.90e-02 | 37 |
| hsa041101 | Colorectum | FAP | Cell cycle | 37/1404 | 157/8465 | 1.44e-02 | 4.77e-02 | 2.90e-02 | 37 |
| hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa0520325 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
| hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa0520335 | Esophagus | ESCC | Viral carcinogenesis | 137/4205 | 204/8465 | 2.47e-07 | 1.88e-06 | 9.62e-07 | 137 |
| hsa052034 | Lung | IAC | Viral carcinogenesis | 43/1053 | 204/8465 | 3.02e-04 | 3.07e-03 | 2.04e-03 | 43 |
| hsa041105 | Lung | IAC | Cell cycle | 30/1053 | 157/8465 | 1.03e-02 | 3.83e-02 | 2.54e-02 | 30 |
| hsa0520311 | Lung | IAC | Viral carcinogenesis | 43/1053 | 204/8465 | 3.02e-04 | 3.07e-03 | 2.04e-03 | 43 |
| hsa0411012 | Lung | IAC | Cell cycle | 30/1053 | 157/8465 | 1.03e-02 | 3.83e-02 | 2.54e-02 | 30 |
| hsa0520321 | Lung | AIS | Viral carcinogenesis | 37/961 | 204/8465 | 2.49e-03 | 1.49e-02 | 9.55e-03 | 37 |
| hsa0520331 | Lung | AIS | Viral carcinogenesis | 37/961 | 204/8465 | 2.49e-03 | 1.49e-02 | 9.55e-03 | 37 |
| hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| hsa052038 | Oral cavity | OSCC | Viral carcinogenesis | 124/3704 | 204/8465 | 5.57e-07 | 3.28e-06 | 1.67e-06 | 124 |
| hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
| hsa0520314 | Oral cavity | OSCC | Viral carcinogenesis | 124/3704 | 204/8465 | 5.57e-07 | 3.28e-06 | 1.67e-06 | 124 |
| hsa0520342 | Oral cavity | EOLP | Viral carcinogenesis | 55/1218 | 204/8465 | 1.54e-06 | 1.34e-05 | 7.92e-06 | 55 |
| hsa0411041 | Oral cavity | EOLP | Cell cycle | 42/1218 | 157/8465 | 3.20e-05 | 1.61e-04 | 9.52e-05 | 42 |
| hsa0520351 | Oral cavity | EOLP | Viral carcinogenesis | 55/1218 | 204/8465 | 1.54e-06 | 1.34e-05 | 7.92e-06 | 55 |
| hsa0411051 | Oral cavity | EOLP | Cell cycle | 42/1218 | 157/8465 | 3.20e-05 | 1.61e-04 | 9.52e-05 | 42 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HDAC8 | SNV | Missense_Mutation | c.1106T>A | p.Ile369Asn | p.I369N | Q9BY41 | protein_coding | deleterious(0) | benign(0.388) | TCGA-A2-A0YF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Arimidex | SD | |
| HDAC8 | SNV | Missense_Mutation | c.463N>G | p.Leu155Val | p.L155V | Q9BY41 | protein_coding | tolerated(1) | benign(0.003) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| HDAC8 | SNV | Missense_Mutation | rs397515417 | c.932N>T | p.Thr311Met | p.T311M | Q9BY41 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
| HDAC8 | insertion | In_Frame_Ins | novel | c.365_366insAAGATATATTGTTTCCCCTACCAAGTTTGAAAAAGATTCTTT | p.Ala122_Ala123insArgTyrIleValSerProThrLysPheGluLysAspSerPhe | p.A122_A123insRYIVSPTKFEKDSF | Q9BY41 | protein_coding | TCGA-A7-A0CD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| HDAC8 | insertion | Nonsense_Mutation | novel | c.141_142insGGAGAATCGCTTGAACCCCGGAGGTGAAGG | p.Ala47_Tyr48insGlyGluSerLeuGluProArgArgTerArg | p.A47_Y48insGESLEPRR*R | Q9BY41 | protein_coding | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
| HDAC8 | SNV | Missense_Mutation | novel | c.926N>T | p.Ala309Val | p.A309V | Q9BY41 | protein_coding | tolerated(0.19) | benign(0.076) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| HDAC8 | SNV | Missense_Mutation | c.567N>G | p.Phe189Leu | p.F189L | Q9BY41 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-BI-A0VR-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| HDAC8 | SNV | Missense_Mutation | novel | c.425A>G | p.His142Arg | p.H142R | Q9BY41 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| HDAC8 | SNV | Missense_Mutation | c.170T>G | p.Val57Gly | p.V57G | Q9BY41 | protein_coding | deleterious(0) | possibly_damaging(0.623) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| HDAC8 | SNV | Missense_Mutation | novel | c.616N>A | p.Gly206Arg | p.G206R | Q9BY41 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | PMID29671355-Compound-67 | |||
| 55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 187051799 | DACINOSTAT | |
| 55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | PMID29671355-Compound-37 | |||
| 55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | PCI-24781 | ABEXINOSTAT | |
| 55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | PHENYLBUTANOIC ACID | PHENYLBUTANOIC ACID | 24044874 | |
| 55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | VORINOSTAT | VORINOSTAT | ||
| 55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | PANOBINOSTAT | PANOBINOSTAT | |
| 55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | PHENYLBUTYRYLHYDROXAMIC ACID | PHENYLBUTYRYLHYDROXAMIC ACID | 21874153 | |
| 55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | PMID29671355-Compound-25 | |||
| 55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 187051793 | GIVINOSTAT |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |